Regentis Biomaterials (NYSE American: RGNT) has announced plans to begin European surgeon training activities in the third quarter of 2026 as part of preparations for the commercial rollout of GelrinC(R), its CE Mark-approved treatment for knee cartilage lesions. The hands-on program will provide orthopedic surgeons with practical experience using the company’s cell-free implant and is expected to begin at Humanitas Research Hospital in Milan, Italy, with additional sessions planned across Europe.
The company said the training initiative is a key step in its European commercialization strategy and will be supported by a network of Centers of Excellence focused on surgeon education, clinical guidance and knowledge sharing. GelrinC is designed as a ready-to-use, single-step implant procedure for knee cartilage repair, and Regentis believes expanding physician familiarity with the technology will support adoption as the product enters broader clinical use.
Regentis Biomaterials is a regenerative medicine company dedicated to developing innovative tissue repair solutions that restore health and enhance quality of life. With an initial focus on orthopedic treatments, Regentis’ Gelrin platform technology, based on synchronized, degradable hydrogel implants, regenerates damaged or diseased tissue including inflamed cartilage and bone. GelrinC is a cell-free, off-the-shelf hydrogel that is eroded and resorbed in the knee, allowing the surrounding cells to regenerate the cartilage in a controlled and synchronous process. GelrinC aims to address a market of approximately 470,000 cases for cartilage knee repair annually in the U.S. where no off-the-shelf treatment is available.
The announcement underscores Regentis's commitment to bringing GelrinC to European patients and surgeons. The training program is designed to ensure that surgeons are proficient in the implantation technique, which is critical for achieving optimal patient outcomes. By establishing Centers of Excellence, Regentis aims to create a network of leading orthopedic institutions that can serve as reference sites for other surgeons learning the procedure.
The importance of this development lies in the potential for GelrinC to fill a significant gap in the treatment of knee cartilage lesions. Currently, many patients with cartilage damage face limited options, particularly those who are not candidates for more invasive procedures like microfracture or autologous chondrocyte implantation. GelrinC offers a one-step, off-the-shelf solution that could simplify the surgical process and reduce recovery times.
For more information on Regentis Biomaterials and GelrinC, visit the company's newsroom at https://ibn.fm/RGNT.
